CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

That widely missed Larew's estimate for $27.1 million. Chromium, 10x's oldest system, brought in $7.6 million. Its spatial ...

Nisa Investment Advisors LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 16,500 shares of the ...

It believes Chromium will sustain “greater volume declines and/or pricing pressure than current management expectations, and thus perpetuate 10x Genomics’ margin degradation.” The bank sees ...

Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, and a low estimate of $14.00. Experiencing a 19.71% decline, the current ...

10x Genomics (NASDAQ:TXG) has built a reputation as a trailblazer in recent years, with cutting-edge single-cell and spatial technologies. The firm's Chromium, Visium and Xenium platforms have ...

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on TXG stock, giving a Buy rating on January 13.Stay Ahead of the ...

Increased cumulative instruments sold to more than 7,000 instruments as of the end of 2024, which includes over 5,800 Chromium instruments ... Co-founder and CEO of 10x Genomics.

Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from ...